Lykos Therapeutics, formerly MAPS Public Benefit Corporation, has announced it has received FDA acceptance and priority review for a New...
Doctors have raised a warning against so-called “trip killers” that are used to end challenging psychedelic experiences on compounds such as LSD or psilocybin.
Dr Peter Sjöstedt-Hughes, Lecturer at Exeter University, has proposed incorporating metaphysical philosophy into psychedelic therapy to help improve therapeutic outcomes.
Silo Pharma has announced it has advanced the formulation development for its therapeutic drug, SPC-15, which utilises ketamine.
Alcohol use disorders (AUD) are estimated to affect around 237 million people across the globe, with 3 million deaths each year attributed to the harmful use...
Authorised psychiatrists are now able to prescribe MDMA and psilocybin for PTSD and treatment-resistant depression, respectively, from 1 July.
COMPASS Pathways and MAPS Public Benefit Corporation (PBC) have put forward a joint application for a new code to facilitate access to psychedelic therapies in the...
Lucy Scientific Discovery is partnering with non-profit organization that advocates for legal access to psilocybin therapy for Canadians, TheraPsil, to advance medical access and research.
In a partnership that has been described as “an important step to reintroduce psychedelics into society”, Dimensions and the New Health Club are joining together to...
Dr Devon Christie, Medical and Therapeutic Services Director with Numinus, speaks to Psychedelic Health about the representation of women in the field of psychedelics – from...
